Charles Schwab Investment Management Inc. Trims Stock Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Elanco Animal Health by 4.6% in Q1, now owning approximately 4.47 million shares valued at $46.95 million.
• Analysts have upgraded Elanco Animal Health's stock ratings, with a consensus price target of $17.33 and several firms assigning a "buy" or "strong-buy" rating.
• Elanco's recent earnings report beat expectations, showing $0.26 EPS against estimates of $0.20, and revenue of $1.24 billion, a 4.8% increase year-over-year.

Charles Schwab Investment Management Inc. reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,471,598 shares of the company's stock after selling 216,012 shares during the period. Charles Schwab Investment Management Inc. owned 0.90% of Elanco Animal Health worth $46,952,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ELAN. Allworth Financial LP lifted its position in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares in the last quarter. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health during the fourth quarter valued at about $29,000. NBC Securities Inc. bought a new position in shares of Elanco Animal Health during the first quarter valued at about $40,000. Parallel Advisors LLC lifted its position in shares of Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. UBS Group lifted their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research report on Thursday, July 17th. Stifel Nicolaus lifted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. Finally, Piper Sandler lifted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.0450 during trading hours on Thursday, hitting $17.5050. The company's stock had a trading volume of 6,855,970 shares, compared to its average volume of 6,544,357. The company has a market cap of $8.70 billion, a price-to-earnings ratio of 20.35, a PEG ratio of 3.24 and a beta of 1.66. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The business has a 50 day simple moving average of $15.00 and a two-hundred day simple moving average of $12.42. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.08.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.